UNK-Long is UNIKE's proprietary long-acting protein drug platform. Based on our self-developed ZT technology, it extends protein half-life from hours to days or even months, significantly reducing injection frequency and improving patient compliance.
Advantages
Extended Half-Life
Significantly extends drug half-life, reducing injection frequency from once daily to once weekly or even once every four weeks.
Low Immunogenicity
Derived from natural human proteins with low immunogenicity.
Low Cost
E. coli fermentation delivers high yield with simple purification, at only 1/10–1/5 of the cost of other technologies.
Short R&D Cycle
Fast molecular design and simple conjugation enable short fermentation cycles and rapid product iteration.
Flexible Design
Multiple conjugation sites enable easy design of multi-target, multi-functional fusion proteins.
Broad Applicability
Suitable for peptides, proteins and enzymes ranging from a few to hundreds of amino acids.
Principle
Short half-life is a key factor limiting the clinical application of protein drugs. UNK-Long increases the hydrodynamic radius of proteins through ZT technology, leverages in vivo recycling mechanisms, or improves degradation resistance, thereby significantly extending drug retention time. The platform has established a standardized process for long-acting molecular design, from target analysis and molecular construction to activity evaluation and pharmacokinetic studies, enabling standardized, versatile, low-cost and efficient drug development.
Applications
UNK-Long has been successfully applied to multiple pipeline candidates including long-acting GLP-1 receptor agonists and long-acting growth hormone. The long-acting GLP-1 receptor agonist enables dosing once every two weeks to once monthly. The long-acting technology significantly reduces injection frequency from daily to weekly or even monthly, greatly improving patient compliance and quality of life.
